Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Capital Expenditures (2017)

vTv Therapeutics' Capital Expenditures history spans 3 years, with the latest figure at $18000.0 for Q4 2017.

  • For Q4 2017, Capital Expenditures changed N/A year-over-year to $18000.0; the TTM value through Dec 2021 reached $18000.0, changed N/A, while the annual FY2022 figure was $21000.0, N/A changed from the prior year.
  • Capital Expenditures for Q4 2017 was $18000.0 at vTv Therapeutics, down from $39000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $62000.0 in Q4 2015 and bottomed at -$2000.0 in Q4 2014.
  • The 3-year median for Capital Expenditures is $13500.0 (2014), against an average of $21000.0.
  • The largest YoY upside for Capital Expenditures was 3200.0% in 2015 against a maximum downside of 0.0% in 2015.
  • A 3-year view of Capital Expenditures shows it stood at -$2000.0 in 2014, then surged by 3200.0% to $62000.0 in 2015, then plummeted by 70.97% to $18000.0 in 2017.
  • Per Business Quant, the three most recent readings for VTVT's Capital Expenditures are $18000.0 (Q4 2017), $39000.0 (Q1 2017), and $62000.0 (Q4 2015).